Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.57 |
| ▸ | PARP1 | P09874 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014455 | 1.00 | KIF11 (0.57) | KIF11PARP1RAB9ADYRK1ACSNK2A1 | |
| SCHEMBL23863111 | 0.91 | KIF11 (0.60) | KIF11PARP1RAB9ADYRK1ACSNK2A1 | |
| SCHEMBL20997558 | 0.86 | KIF11 (0.55) | KIF11PARP1RAB9ADYRK1ACSNK2A1 | |
| SCHEMBL3118866 | 0.84 | KIF11 (0.52) | KIF11PARP1RAB9ADYRK1ACSNK2A1 | |
| SCHEMBL3195750 | 0.82 | KIF11 (0.53) | KIF11PARP1RAB9ADYRK1ACSNK2A1 | |
| SCHEMBL349187 | 0.82 | PARP1 (0.49) | KIF11PARP1DYRK1ACSNK2A1JAK2 | |
| SCHEMBL4725998 | 0.80 | KIF11 (0.84) | KIF11PARP1RAB9ADYRK1ACSNK2A1 | |
| SCHEMBL29708168 | 0.80 | KIF11 (0.84) | KIF11PARP1RAB9ADYRK1ACSNK2A1 | |
| SCHEMBL1547766 | 0.79 | KDM4E (0.56) | DYRK1AJAK2KMT2AALDH1A1KDM4E | |
| SCHEMBL27763589 | 0.78 | KIF11 (0.49) | KIF11PARP1RAB9ADYRK1ACSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076466-B1 | MODULATORS OF CULLIN 3 ADAPTOR KBTBD4 AS ANTI-CANCER COMPOUNDS | UNIV MONTREAL (CA) | 2026-03-11 | — | — | EP | disclosed |
| CN-114845719-A | Modulators of the CULLIN3 connexin kbbd 4 as anti-cancer compounds | 蒙特利尔大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-107208111-B | Compounds and methods for enhancing viral gene transfer to human hematopoietic cells | 蒙特利尔大学 | 2021-07-06 | — | — | CN | disclosed |
| WO-2021119834-A1 | MODULATORS OF CULLIN 3 ADAPTOR KBTBD4 AS ANTI-CANCER COMPOUNDS | UNIVERSITE DE MONTREAL (CA) | 2021-06-24 | — | — | WO | disclosed |
| EP-3194602-B1 | COMPOUNDS AND METHODS FOR ENHANCING VIRAL GENE TRANSFER TO HUMAN HEMATOPOIETIC CELLS | UNIV MONTREAL (CA) | 2019-11-06 | — | — | EP | disclosed |
| US-10336747-B2 | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells | Université de Montréal | 2019-07-02 | — | — | US | disclosed |
| US-10336747-B2 | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells | Université de Montréal | 2019-07-02 | — | — | US | disclosed |
| EP-2807165-B1 | PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS | UNIV MONTREAL (CA) | 2019-05-15 | — | — | EP | disclosed |
| EP-2807165-B1 | PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS | UNIV MONTREAL (CA) | 2019-05-15 | — | — | EP | disclosed |
| US-10273503-B2 | Compounds and methods for enhancing viral gene transfer to human hematopoietic cells | UNIVERSITE DE MONTREAL (CA) | 2019-04-30 | — | — | US | disclosed |
| WO-2013110198-A1 | PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS | Université de Montréal (CA) | 2013-08-01 | — | — | WO | disclosed |
| EP-2119703-B1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273503-B2 | Compounds and methods for enhancing viral gene transfer to human hematopoietic cells | HCLS1, INMT, IDO1 | KIF11 1853/4885PARP1 1526/4885RAB9A 2763/4885 |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | NFKBIA, IKBKB, IKBKG | KIF11 2732/4885PARP1 2812/4885RAB9A 3159/4885 |
| US-10336747-B2 | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells | IDO1, IDO2, INMT | KIF11 4023/4885PARP1 872/4885RAB9A 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.